Understanding a protein's role in liver cancer growth
Role of heat shock transcription factor HSF1 in tumorigenesis
This work explores how a specific protein called HSF1 helps liver cancer cells grow and adapt, aiming to find new ways to treat this challenging disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Augusta University NIH-funded |
| Lab location | 1 site (Augusta, United States) |
| Project ID | NIH-11063971 on NIH RePORTER |
What this research studies
Liver cancer, especially hepatocellular carcinoma (HCC), is a very aggressive cancer that is often hard to treat and frequently comes back after surgery. Current treatments like chemotherapy and immunotherapy don't work for everyone, highlighting a need for new approaches. This project aims to understand how a protein called HSF1 contributes to the growth and resilience of liver cancer cells. By uncovering these fundamental mechanisms, we hope to identify new targets for more effective therapies. Our goal is to develop better strategies to overcome treatment resistance and improve outcomes for patients with liver cancer.
Who could benefit from this research
Good fit: This foundational research is relevant to patients with hepatocellular carcinoma (HCC), particularly those whose tumors are resistant to current therapies.
Not a fit: Patients without liver cancer or those whose cancer is not related to the HSF1 pathway may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new targets for drugs, offering more effective treatments for liver cancer patients who currently have limited options.
How similar studies have performed: While current immunotherapies for liver cancer have shown limited success for many patients, this work explores novel mechanisms that could lead to entirely new therapeutic strategies.
Where this research is happening
Augusta, United States
- Augusta University — Augusta, United States (Active)
Researchers
- Principal investigator: Mivechi, Nahid F — Augusta University
- Study coordinator: Mivechi, Nahid F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.